

# Brain galanin system genes interact with life stresses in depression-related phenotypes

Gabriella Juhasz<sup>a,b,c,1</sup>, Gabor Hullam<sup>b,d</sup>, Nora Eszlar<sup>a,b</sup>, Xenia Gonda<sup>a,b,e</sup>, Peter Antal<sup>d</sup>, Ian Muir Anderson<sup>c</sup>, Tomas G. M. Hökfelt<sup>f,1</sup>, J. F. William Deakin<sup>c,g</sup>, and Gyorgy Bagdy<sup>a,b</sup>

<sup>a</sup>Department of Pharmacodynamics, Semmelweis University, 1089, Budapest, Hungary; <sup>b</sup>MTA-SE Neuropsychopharmacology and Neurochemistry Research Group, Hungarian Academy of Sciences, 1089, Budapest, Hungary; <sup>c</sup>Neuroscience and Psychiatry Unit, University of Manchester, Manchester M13 9PT, United Kingdom; <sup>d</sup>Department of Measurement and Information Systems, Budapest University of Technology and Economics, 1117, Budapest, Hungary; <sup>e</sup>Department of Clinical and Theoretical Mental Health, Semmelweis University, 1125, Budapest, Hungary; <sup>f</sup>Department of Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden; and <sup>g</sup>Manchester Mental Health and Social Care Trust, Manchester M21 9UN, United Kingdom

Contributed by Tomas G. M. Hökfelt, February 28, 2014 (sent for review January 20, 2014)

**Galanin is a stress-inducible neuropeptide and cotransmitter in serotonin and norepinephrine neurons with a possible role in stress-related disorders. Here we report that variants in genes for galanin (*GAL*) and its receptors (*GALR1*, *GALR2*, *GALR3*), despite their disparate genomic loci, conferred increased risk of depression and anxiety in people who experienced childhood adversity or recent negative life events in a European white population cohort totaling 2,361 from Manchester, United Kingdom and Budapest, Hungary. Bayesian multivariate analysis revealed a greater relevance of galanin system genes in highly stressed subjects compared with subjects with moderate or low life stress. Using the same method, the effect of the galanin system genes was stronger than the effect of the well-studied *5-HTTLPR* polymorphism in the serotonin transporter gene (*SLC6A4*). Conventional multivariate analysis using general linear models demonstrated that interaction of galanin system genes with life stressors explained more variance (1.7%,  $P = 0.005$ ) than the life stress-only model. This effect replicated in independent analysis of the Manchester and Budapest subpopulations, and in males and females. The results suggest that the galanin pathway plays an important role in the pathogenesis of depression in humans by increasing the vulnerability to early and recent psychosocial stress. Correcting abnormal galanin function in depression could prove to be a novel target for drug development. The findings further emphasize the importance of modeling environmental interaction in finding new genes for depression.**

galanin receptors | mood disorders | network-based analysis | neurogenesis | transmitter coexistence

**M**ajor depressive disorder (MDD) is a common and serious disease afflicting more women than men, and a leading cause of disability worldwide, associated with much suffering and major costs for society (1, 2). Environmental psychosocial stressors are important in pathogenesis, because episodes are usually preceded by adverse life events, and early childhood experiences of physical and emotional abuse and parental neglect are important vulnerability factors (3, 4). Genetic vulnerability is significant with a heritability of about 35% (5). We remain ignorant about the brain processes that translate these genetic and environmental influences into depressive symptoms or risk. A major clue is that effective antidepressant drugs act directly or indirectly to enhance neurotransmission in serotonin (5-HT) and norepinephrine monoamine pathways, proving the monoamine hypothesis of depression (6–8). Many other candidate mechanisms have been identified in anatomical, pharmacological, and behavioral studies of stress in rodents. However, the demonstration of state- or trait-related abnormalities in human monoamine or other neural systems remains frustratingly elusive, despite modern brain-imaging methods. To determine whether the neuropeptide galanin has a role in depression, we used a unique Bayesian systems-based analysis to dissect out the influence of variation in

genes for the peptide and its receptors on the interaction between different psychosocial stressors and risk of depression.

Current drug treatment of depression is far from satisfactory; the drugs target a limited range of monoamine mechanisms, they have an appreciable side-effect burden, and response is often partial (8, 9). In the search for better antidepressants, much attention has focused on neuropeptides and their receptors, the most diverse neurotransmitter system in the brain (8, 10–21), which includes galanin. As yet, however, there is no compelling evidence of efficacy of the neuropeptide approach or that particular peptides are involved in the pathogenesis of MDD.

Galanin, a 29-aa (30 in humans) peptide (22), is widely distributed in the rodent (23, 24) and human (25–27) brain. In rat it coexists with noradrenaline (NA) in the locus coeruleus (LC) and with 5-HT in the dorsal raphe complex (28). Like other peptide cotransmitters (29), it is released when neurons fire in high-frequency bursts in response to strong behavioral and pharmacological challenge (30–32). Galanin exerts its action via three cloned receptors, GALR1, GALR2, and GALR3 (33, 34) with a broad distribution in rat (35) and primate brain (26, 36). Animal behavioral studies (31, 32, 37–41) and a single study in humans (42) suggest that galanin has a role in stress, depression-like behavior, and anxiety. In addition, there is indication from

## Significance

**Early and recent environmental stressors, such as maltreatment in childhood, or stressful life events in adulthood, are important risk factors for depression. Nevertheless, not all people who suffer from these will be depressed. The resilience or vulnerability to these stressors, and thus depression, is likely to reside in our genes. In the present study, we used different statistical methods to demonstrate that variations in genes for galanin and its receptors increase the risk of depression only in heavily stress-exposed subjects. The work was predicated on the finding that galanin expression is strongly stimulated by stress in animal studies. In humans, variation in galanin function would appear to be important determinants of the outcome of psychosocial stress.**

Author contributions: G.J., X.G., I.M.A., J.F.W.D., and G.B. designed research; G.J., G.H., N.E., and P.A. analyzed data; G.J., P.A., T.G.M.H., J.F.W.D., and G.B. wrote the paper; and G.J., X.G., and G.B. harmonized the methods between the two sites.

Conflict of interest statement: J.F.W.D. variously performed consultancy, speaking engagements, and research for Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Schering Plough, Janssen-Cilag, and Servier (all fees are paid to the University of Manchester to reimburse them for the time taken); he also has share options in P1vital. I.M.A. received an honorarium for speaking from Lundbeck and grant support from Servier and AstraZeneca. T.G.M.H. consulted with Synaptic and received an honorarium (2005).

Freely available online through the PNAS open access option.

<sup>1</sup>To whom correspondence may be addressed. E-mail: gabriella.juhasz@manchester.ac.uk or tomas.hokfelt@ki.se.


This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1403649111/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1403649111/-DCSupplemental).

previous genetic studies on humans that the galanin system is involved in psychiatric disorders including alcoholism/addiction (43–47), panic disorder (48, 49), and chronic pain-associated depression (50). Furthermore, recent functional studies provided the first evidence that polymorphisms in a highly conserved genetic region upstream from the *GAL* gene regulates *GAL* expression in brain areas, such as the amygdala and hypothalamus, implicated in the pathogenesis of depression (51, 52).

Genetic studies have the potential to identify molecular mechanisms of MDD vulnerability (53), but even mega- and meta-analyses of large genome-wide association studies (GWAS) have not identified genetic variants associated with MDD that survive genome-wide statistical correction (54, 55). Nominally significant associations will include many false-positives. Nevertheless it is noteworthy that SNPs in the gene for galanin (*GAL*) were among the top 10 genes whose variation was associated with MDD in a recent GWAS (55). One way to improve sensitivity is to take a system-based approach: if galanin is mechanistically involved in depression, genetic variation in the peptide and its receptors should exert similar influences, despite the fact the genes are located on entirely different chromosomes without linkage disequilibrium (LD) and with a low probability of randomly similar effects. Others have argued that improved sensitivity will come from deeper phenotyping (56) and characterization of environmental factors (3, 4, 57), because neither genetic nor environmental factors can be identified in isolation, if they modify each other's action to a high degree. Combining these two approaches, and in view of its preclinical properties, we predicted that variation in galanin genes would strongly interact with environmental stress in determining depression vulnerability. However, including more phenotypic and environmental variables exacerbates the problem of false-positives from multiple comparisons. Consequently, analyses of gene–environment interactions involving multiple phenotypes face a similar burden as GWAS in terms of correction for multiple testing. Furthermore, the conditional nature of such interactions frequently leads to separate analysis of multiple subpopulations (i.e., to even more statistical tests). To cope with multiple hypothesis testing, we applied a Bayesian systems-based approach both at structural and parametric levels, which allows multiple correlated outcomes. This approach supported the joint exploration of the underlying mechanism at genotype, haplotype, and diplotype levels in different depression-related phenotypes, and we validated the results by conventional multivariate analysis using independent subsamples.

## Results

**Genetic Association and Gene × Environment Interaction Analysis with Linear and Logistic Regression.** Table 1 summarizes the demographic and phenotypic characteristic of the studied population. To show the genetic effects alone or in interaction with environmental factors, the effects of single SNPs (*SI Methods*, Figs. S1–S4, and Table S1) and their combination (haplotypes, HT) (Table S2) were studied. First, we carried out a traditional linear and logistic regression analysis using additive genotypic and diplotypic models for the selected variables. (For power calculations see *SI Methods* and Table S3.) Of the 12 SNPs studied, 7 statistically associated with one or more of the three clinical phenotypes (Fig. 1). Furthermore, all but one (*GAL* rs3136541) of the seven acted through interaction with either childhood adversity or recent life events. Two of the six *GALRI* SNPs interacted with recent life events (rs1893829, rs1162010) and two with childhood adversity (rs5375, rs11665337) to influence phenotypes. Three *GALRI* haplotypes (HT2:GAGTAG, HT6:GAGTGA, HT12:GGTCGG) interacted with childhood adversity and one with recent life events (HT10:AAGCAG). The single SNP representing *GALR2* (rs8836) interacted with life events, whereas a *GALR3* SNP (rs2285179) and the main haplotype (HT1:GA) interacted with childhood adversity. These



**Fig. 1.** Summary figure of the SNP association and SNP × environment interaction results. This figure shows the  $-\log P$  values (vertical axis) of the genetic main effects (G), gene and childhood adversity interaction (G×CHA), and gene and recent negative life events interaction (G×RLE) analysis (additive genetic model in PLINK v1.07, <http://pngu.mgh.harvard.edu/purcell/plink>). The red line represents  $P = 0.05$  nominal significance level; above that line significant results can be seen. Outcome variables were lifetime depression (DEP), current depression scores (BSIDEF), and current anxiety scores (BSIANX). Age and sex were covariate in all analysis. Horizontal axis lists the investigated SNPs, the genes and their chromosomal positions, and the tagged functional variants based on in silico functional analysis (see also Table S7). TFBS, transcription factor-binding site; splicing, SNPs that are located at 2 base pairs of intron–exon junction region; miRNA, miRNA binding site activity; nsSNP, SNPs in protein-coding regions that can cause amino acid change; stop codon, SNPs that may lead to premature termination of peptides (nonsense), which would disable the protein function.

nominally significant findings can be seen in Tables S4 and S5, which summarize all of the regression results. The results suggested to us that *GALRI* and probably *GALR3* modulate neurodevelopmental processes relevant to the effects of childhood adversity, whereas *GALR2* might modulate neuroplastic changes connected with stress responses to recent life events. Despite their interest and the corroboration that functionally related, genomically distant genes show similar gene-by-environment (G×E) interactions, these nominally significant effects did not survive Bonferroni correction for multiple testing. To reach an optimal correction for multiple-hypotheses testing concerning the numerous potential dependencies between multiple predictors and phenotypes, we applied a systems-based approach in the second phase using the Bayesian model averaging framework (58–60). This approach allowed the principled and detailed investigation of G×E interactions as model properties. The analysis consisted of a joint multivariate analysis of *GAL*, *GALRI*, *GALR2*, and *GALR3* genes on all three phenotypes—reported lifetime depression, current depression, and anxiety—both in the Bayesian and conventional (traditional regression) statistical framework.

**Bayesian Network-Based Bayesian Multilevel Analysis of Relevance.** Bayesian network-based Bayesian multilevel analysis (BN-BMLA) was carried out using a method that allows a detailed investigation of the relevance of factors with respect to multiple dependent variables such as phenotype descriptors (61). The resulting scores are posterior probabilities of relevance (Pr) ranging from 0 to 1. This method involves Bayesian model averaging over possible models reflecting relationships between variables, thus handling the multiple hypothesis testing problem optimally by taking into consideration the potential interdependencies of the predictors (for detailed description of the BN-BMLA method, see *SI Methods*).



In addition, further testing the relevance of the *5-HTTLPR* and the galanin system genes in one model in those who experienced high level of recent negative life events, the relevance of the galanin system genes remained stable, whereas the relevance of the *5-HTTLPR* modestly decreased (from  $Pr = 0.55$  to  $Pr = 0.34$ ). This result suggests that the effect of the *5-HTTLPR* may be partially mediated by the galanin system but not vice versa. These results corroborate previous findings and suggest that the galanin system probably has similar or stronger effect on stress-induced depressive symptoms compared with the *5-HTTLPR* functional polymorphism.

**Galanin Pathway Level Analysis.** To assess the overall contribution of galanin genes to variation in risk of our depression-related phenotypes, two general linear models were constructed: a “Reduced” model containing only environmental factors (childhood adversity and recent negative life events), and a “Full” model containing environmental factors, genetic factors (*GAL*, *GALRI*, *GALR2*, *GALR3*), and their interactions. Table 2 shows residual variances for the phenotypes, namely reported lifetime depression, current depression, and anxiety separately, and also for the multivariate case (i.e., combining the variance across all phenotypes). The results indicate that the Full model explains more variance, resulting in less residual or unexplained variance in every case than the life stress-only model. In the overall multivariate case the difference is 0.017, which means that the investigated genetic variants and their interactions with life stressors contribute 1.7% to the total variance. In our study, the difference between the Full and Reduced models in the multivariate comparison was significant ( $F = 1.838$ ,  $F_{critical} = 1.759$ ,  $\alpha < 0.005$ ). This effect was significant separately for the population recruited in Budapest ( $F = 1.632$ ,  $F_{critical} = 1.452$ ,  $\alpha < 0.05$ ) and in Manchester ( $F = 1.531$ ,  $F_{critical} = 1.448$ ,  $\alpha < 0.05$ ), and in the combined sample separately both in males ( $F = 1.645$ ,  $F_{critical} = 1.459$ ,  $\alpha < 0.05$ ) and in females ( $F = 2.108$ ,  $F_{critical} = 2.039$ ,  $\alpha < 0.0005$ ) with similar magnitude of effect size (3.9% vs. 3%, respectively). Conducting the comparison of the models for the phenotypes individually in the combined sample showed that the difference between the models was most significant in case of the current depression phenotype ( $F = 2.174$ ,  $F_{critical} = 2.031$ ,  $\alpha < 0.0005$ ).

**In Silico Functional Analysis and Comparison with Psychiatric Genetic Consortium GWAS Results.** Finally, in silico functional prediction was carried out using the SNP Function Prediction (FuncPred) tool (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>). This process revealed that two of our investigated SNPs have functional effects. Namely, rs11662010 (near to the 5' end of the *GALRI* gene) modifies a transcription factor binding site, and rs8836 (downstream to the *GALR2* gene in strong LD with it) has miRNA binding activity. In addition, our 12 haplotype tag SNPs captured an additional 23 potentially functional variants within the galanin system (Fig. 1), suggesting that the genetic regions covered by our haplotype-tagging SNPs have functional consequences on the gene transcription and translation, thus may reflect real functional differences (Table S7). In addition, the Psychiatric Genetic Consortium's latest mega-analysis showed several nominally significant associations and trends between MDD and the *GAL*, and *GALRI* genes (Table S7), further supporting our results.

## Discussion

Galanin is, as revealed in animal experiments, a highly “dynamic” neuropeptide, frequently showing a robust up-regulation of expression in response to stress, both under physiological and extreme conditions. We tested the hypothesis that the genetic effects of the galanin system in the development of depression and anxiety would be greatest in those exposed to the most life stress. In the present study, genetic variants of *GALRI* significantly interacted with childhood adversity, suggesting it also has a role in neuronal damage and wiring during neuronal development. The interaction of *GALRI* SNPs and childhood adversity in the regression analysis was confirmed by the Bayesian multivariate analysis of relevance. Moreover, *GALR2* rs8836 significantly moderated the effect of recent negative life events, also confirmed by the Bayesian analysis. In addition, *GALR3* showed a moderate relevance in interaction with recent negative life events in our study. Finally, high log posterior ratios indicated that *GAL* gene effect was more relevant in the highly stressed population compared with the low or moderately stressed subjects. These results indicate that the galanin pathway has a role in the development of depression in humans but only in persons exposed to high levels of childhood adversity or recent


**Table 1. Demographic and phenotypic characteristic of the sample**

Demographics	Combined	Budapest	Manchester
Sex			
Female	1,641 (70%)	702 (69%)	939 (70%)
Male	720 (30%)	313 (31%)	407 (30%)
Age (mean $\pm$ SEM)	32.8 $\pm$ 0.2	31.1 $\pm$ 0.3	34.0 $\pm$ 0.3
Personal psychiatric history			
Reported depression	974 (41%)	217 (21%)	757 (56%)
Recurrent episodes	690 (71%)	118 (54%)	572 (76%)
Ever treated with antidepressant	637 (65%)	70 (32%)	567 (75%)
Reported suicide attempt	285 (12%)	48 (5%)	237 (18%)
Reported anxiety disorder	641 (27%)	202 (20%)	439 (33%)
Reported substance use disorder	130 (6%)	24 (2%)	106 (8%)
Family psychiatric history			
Reported depression in immediate blood relatives	632 (27%)	135 (13%)	497(37%)
Symptom scores (range 0–4)			
BSI depression (mean $\pm$ SEM)	0.85 $\pm$ 0.02	0.56 $\pm$ 0.02	1.08 $\pm$ 0.03
BSI anxiety (mean $\pm$ SEM)	0.88 $\pm$ 0.02	0.69 $\pm$ 0.02	1.02 $\pm$ 0.03
Adversities			
Recent negative life events (mean $\pm$ SEM)	1.22 $\pm$ 0.03	1.08 $\pm$ 0.04	1.3 $\pm$ 0.04
Childhood adversity (mean $\pm$ SEM)	3.3 $\pm$ 0.07	2.8 $\pm$ 0.09	3.7 $\pm$ 0.1

BSI, Brief Symptom Inventory.

negative life events, and that the different receptors have different roles in mediating the effects of different stressors.

The paradigmatic example of a candidate gene interacting with recent negative life events and childhood adversity is the serotonin transporter gene (*SLC6A4*). This gene has a functional polymorphism in the promoter region (*5-HTTLPR*) (62), whose risk variant is associated with a 50% reduction in serotonin transporter protein and predisposition to depression after negative life events (63–65), although there are negative studies. In our study we used this gene as a benchmark and reference for the Bayesian analysis to allow the comparison of posterior probabilities of relevance. The results of Bayesian analysis supported the relevance of *5-HTTLPR* in stress-related depression, but the galanin system had a stronger effect. Indeed, the investigated genetic variants in the galanin pathway and their interactions with life stressors explained 1.7% of the total variance in the depression-related phenotypes. This is a large proportion in comparison with the 0.6% explained variance by the whole-genome polygenic risk score seen in a recent GWAS mega-analysis for MDD (54). According to the Psychiatric Genetic Consortium suggestion, at least 100,000 MDD cases (plus controls) would be required to achieve GWAS-significant findings for MDD (54). However, our results further emphasize that using subjects with high life stresses, because MDD is a stress-related disorder, could potentially decrease the required number of cases to 5,500–35,000 (Table S3). According to the differential sensitivity hypothesis (57), some risk genotype-by-stress interactions also involve increased sensitivity to beneficial environments, such as social supports.



**Fig. 3.** Galanin mechanisms hypothetically involved in MDD in humans. Galanin, a neuropeptide, and its receptors are colocalized in some monoaminergic neurons in the brain. The galanin system is highly sensitive to experimental and naturalistic stressors. Stress-induced activation of the galanin system represents the first phase in the development of depression. Recent analysis of human brain has shown that the Gi protein-coupled GALR3 (and not GALR1 as in rodents) is the main galanin receptor in NA-LC and probably 5-HT dorsal raphe nucleus cells, and that the Gi protein-coupled GALR1 is the main receptor in the forebrain. Antidepressive effects may be achieved by (i) GALR3 antagonists (71), by reinstating normal monoamine turnover in the brainstem, and by (ii) GALR1 antagonists in the forebrain by normalization of limbic system activity, or by (iii) agonists at GALR2, a Gq protein-coupled receptor, promoting neuroprotection. The present genetic analysis suggests that GALR1 risk variants may compromise galanin signaling during childhood, whereas GALR2 signaling may be influenced by recent negative life events. In addition, all four galanin system genes have relevant roles in the development of depression-related phenotypes in those persons who were highly exposed to life stressors.

However, no protective effects of galanin-related genotypes were seen in the low-stress groups in our study.

Potential mechanisms that may explain the galanin system effect in the development of depression are summarized in Fig. 3. The *GAL* gene is widely expressed in the human brain [e.g., LC, forebrain, amygdala, and hypothalamus (26, 51)], but its involvement in the development of depression is not well understood. Although previous studies indicated that it might have a sex- or estrogen-dependent effect (49), in our study the galanin system genetic variants significantly influenced the depression-related phenotypes both in males and in females, with similar magnitude of effect size, providing evidence that the excessive stress effect is not mediated by sex.

The monoamine neurotransmitters, NA, 5-HT, and dopamine, have been implicated in the mechanism of action of antidepressants and thus the pathogenesis of MDD for more than half a century, and also shown to interact in intricate ways in the development and treatment of this serious disease (6, 7, 66). Some of the effects of galanin may fit into this framework. Involvement of the galanin system in regulation of mood-related behavior in animals has focused on several brain sites, via different mechanisms. For example, in rat galanin may have a prodepressive role via modulating 5-HT<sub>1A</sub> receptors in the forebrain (37, 67) or, when released from soma and dendrites in the LC, via inhibitory GALR1 autoreceptors (68, 69). The same receptor mediates inhibition of pyramidal neurons in the ventral hippocampus (70). Thus, galanin may cooperate with its cotransmitter norepinephrine, both at the LC cell body autoreceptor level and postsynaptically in the hippocampus. However, it is important to note that recent studies demonstrated that in humans GALR3 receptors are more prevalent in the brainstem compared with GALR1, whereas GALR1 is widely expressed in the human forebrain (26). In the 5-HT neuron-rich rat dorsal raphe nucleus/periaqueductal gray, Lu et al. (39) have suggested that mood is controlled through a balance between signaling via prodepressive GALR1/3 (71, 72) and antidepressive GALR2 receptors (38, 39). In the ventral tegmental area galanin inhibits dopamine neurons, inducing depression-like behavior (40).

Accumulating evidence suggests that hippocampal atrophy and loss of dendritic spine synapses are associated with depressive symptoms (73–75), whereas recovery of MDD patients involves normalization of the hippocampal volume (76), possibly related to enhancement of functional synapses (77–79). Interestingly, galanin has been reported to act as a neuroprotective factor for hippocampal neurons (80–82) via GalR2 (83). Moreover, it is now established that adult neural stem/progenitor cells generate new neurons in, for example, the hippocampal granule cell layer (84, 85). Subsequently, the proliferation and integration of neuronal stem cells in this brain region have emerged as a focus in attempts to understand mechanisms underlying stress, depression, and the effects of antidepressants (86–88). In the hippocampus, galanin's trophic and proliferative effects via GALR2/3 receptors, on neuronal stem cells in the subgranular zone in the dentate gyrus (89–91), may be involved and could mediate some of the effects of genetic variation that we have observed. The latter idea has gained more weight in view of the recent report that, in humans, a large subpopulation of hippocampal neurons, constituting one-third of the neurons, is subject to exchange (92), substantiating the first report of adult neurogenesis in humans (93). Thus, in adults 700 neurons are added in the hippocampus each day, and around one-third of the hippocampal neurons constantly renew, involving most neurons in the dentate gyrus (92). Interestingly, galanin was more abundant in mouse embryonic stem cells compared with any other examined tissues (94), and in human stem cells galanin was in the top 50 overexpressed genes (95). Furthermore, galanin receptors can also act through cAMP formation (96), and thus the cyclic AMP-responsive element binding (CREB) signaling pathway (97–99),

which is an important modulator of the brain-derived neurotrophic factor (BDNF) production. BDNF mediates activity-dependent neuroplasticity in the hippocampus and cortex, which is critical to the adaptation of environmental stress and also contribute to antidepressant effects (77, 100, 101). It is interesting to note that our previous study demonstrated that genetic variation in the *CREBI-BDNF-NTRK2* pathway also interacts with childhood adversity to increase risk of depression (102).

There are some limitations of our study. For example, we used self-reported questionnaires to measure lifetime depression, depressive and anxiety symptoms, and negative life events that, although proven and widely used, might be influenced by recall bias. Therefore, we validated them in a subpopulation of 142 during face-to-face interviews showing good reliability (102, 103). In addition, we did not control for the timing of depression and life events. It has been demonstrated that childhood adversity has a long-term effect on the pathogenesis of depression (104), and the questionnaire we used to measure recent (last year) negative life events builds on items with long-term contextual threat (105). Finally, our nominally significant G×E interaction results did not survive traditional correction for multiple testing, which was expected in case of weak genetic effects. However, our Bayesian network-based approach accommodates multiple interdependent outcome variables and predictors (i.e., system genes and life stresses), minimizes the loss of power, and quantitatively characterizes the dependency structure of galanin G×E interactions. Results were also confirmed by conventional multivariate analysis using general linear models and comparatively evaluated against the *5-HTTLPR* as reference. Thus, development of probabilistic graphical model-based methods using Bayesian statistical framework may be essential for detecting G×E interactions in modestly heritable disorders.

In conclusion, the present results indicate that the galanin system plays a significant role in the pathogenesis of depression, almost entirely by modulating the vulnerability to early and recent psychosocial stress. The results validate the galanin system as an illness-related target for novel antidepressant drug development.

In addition, our results support suggestions that G×E interactions may significantly contribute to the “missing heritability” in genome-wide case-control studies that lack environmental measures because of their large scale.

## Methods

**Population.** Population cohorts were recruited in Budapest, Hungary and Manchester, United Kingdom in the European Union-funded NewMood study (New Molecules in Mood Disorders, Sixth Framework Program of the European Union, LSHM-CT-2004-503474) using harmonized phenotyping and genotyping methods that enabled us to carry out a mega-analysis. From the recruited  $n = 2,588$  subjects,  $n = 2,361$  ( $n = 1,015$  from Budapest and  $n = 1,346$  from Manchester) were eligible for this study who filled out the questionnaires, provided DNA, which was successfully genotyped for the galanin pathway, and have European White ethnic origin. Data of all eligible participants were included in the analysis, regardless of reported psychiatric disorders (Table 1). Details of the recruitment strategy and the population cohorts can be read in previous publications (64, 102, 103). In short, we recruited participants aged between 18–60 y from Greater Manchester, United Kingdom through general practices, advertisements, and a Web site, and from Budapest, Hungary, through general practices and advertisements. Participants returning the signed consent form and the questionnaire were then sent a genetic sampling kit, which they returned. Both studies were approved by the local ethics committees and were carried out in accordance with the Declaration of Helsinki. All participants provided written informed consent.

**Phenotypic Assessment.** Three stress-related phenotypic outcome variables were analyzed. Reported lifetime depression was derived from targeted questions of a self-reported questionnaire and was validated in a subpopulation during face-to-face diagnostic interviews (102). To measure current depression and anxiety we used the Brief Symptom Inventory (106) anxiety and depression subscales with additional items for depression. A short version of the Childhood Trauma Questionnaire (107) assessed the experience of emotional and physical abuse and neglect in childhood, as validated in a previous study (102). Recent stressors were assessed using a validated measure of negative life events covering intimate relationships, financial difficulties, illnesses/injuries, and social network problems (105). Further details of the phenotypic measures can be seen in *SI Methods*.

**Table 2. Residual variances for the full models and the reduced models**

Models	Variance			
	Reported lifetime depression	Current depression	Current anxiety	Multivariate
Total sample				
Reduced	0.215	0.727	0.710	0.551
Full	0.210	0.701	0.692	0.534
Explained variance	0.6%	2.7%*	1.8% <sup>†</sup>	1.7% <sup>‡</sup>
Budapest				
Reduced	0.154	0.418	0.464	0.345
Full	0.147	0.387	0.440	0.325
Explained variance	0.7%	3.1% <sup>‡</sup>	2.4%	2.1% <sup>†</sup>
Manchester				
Reduced	0.225	0.888	0.882	0.665
Full	0.216	0.844	0.843	0.634
Explained variance	0.9%	4.4% <sup>†</sup>	4.0% <sup>†</sup>	3.1% <sup>†</sup>
Total males				
Reduced	0.196	0.554	0.501	0.417
Full	0.184	0.501	0.450	0.378
Explained variance	1.2%	5.2% <sup>†</sup>	5.1% <sup>‡</sup>	3.9% <sup>†</sup>
Total females				
Reduced	0.227	0.803	0.798	0.609
Full	0.220	0.759	0.759	0.579
Explained variance	0.7%	4.4%*	3.9%*	3.0%*

\*Significant difference in explained variance  $P < 0.001$ .

<sup>†</sup>Significant difference in explained variance  $0.01 < P \leq 0.05$ .

<sup>‡</sup>Significant difference in explained variance  $0.001 \leq P \leq 0.01$ .

**Genetic Data.** Genetic samples (buccal mucosa cells) were collected according to a validated method (108). Because there are no known functional polymorphisms within this pathway we used haplotype tagging method ([www.broad.mit.edu/personal/jcbarret/haploview](http://www.broad.mit.edu/personal/jcbarret/haploview)) to represent the selected genes and scientific literature to identify previously investigated SNPs. Our haplotype-tagged SNPs capture genetic regions that tend to inherit together ( $LD r^2 > 0.8$ ) in populations with European ancestry [based on the Centre d'Etude du Polymorphisme Humain population data of the International HapMap Project ([www.hapmap.org](http://www.hapmap.org)) Phase I. June 2005]. The selected 12 SNPs (Figs. S1–S4 and Table S1) were genotyped with the Sequenom's MassARRAY technology (Sequenom, [www.sequenom.com](http://www.sequenom.com)). Genotyping was blinded with regard to phenotype and was performed under the ISO 9001:2000 requirements.

**Statistical Analysis.** PLINK v1.07 (<http://pngu.mgh.harvard.edu/purcell/plink>) was used to test additive genetic association using linear and logistic regression models, G $\times$ E interactions, to impute haplotypes (Table S2), and to calculate Hardy–Weinberg equilibrium *P* values. Bayesian and non-Bayesian multivariate analyses were performed to assess the joint effect of *GAL*, *GALR1*, *GALR2*, and *GALR3* on all three phenotypes (reported lifetime depression, current depression, and anxiety). Non-Bayesian statistical analyses were performed with SPSS 21.0 for Windows (IBM). Age and sex were covariates in all analyses. All statistical testing used two-tailed *P* = 0.05 threshold. For detailed

description of the statistical methods and for power calculations, see *SI Methods*. First, we carried out statistical analysis in the total sample because of the moderate sample size, and then replicated our main findings in subpopulations according to study sites (Budapest and Manchester) and sex (female and male).

**ACKNOWLEDGMENTS.** We thank Diana Chase, Emma J. Thomas, Darragh Downey, Kathryn Lloyd-Williams, Judit Lazary, Anita Benko, and Dorottya Pap, for their assistance in the recruitment and data acquisition; Peter Petschner for his assistance in the in silico functional prediction; Hazel Platt for her assistance in genotyping; Heaton Mersey Medical Practice and Cheadle Medical Practice for their assistance in the recruitment; and Mingdong Zhang for valuable help with the manuscript. The study was supported by the Sixth Framework Program of the European Union, NewMood, LSHM-CT-2004-503474; by the National Institute for Health Research Manchester Biomedical Research Centre; the TAMOP-4.2.1.B-09/1/KMR-2010-0001; by the Hungarian Brain Research Program (Grant KTIA\_13\_NAP-A-II/14) and National Development Agency (Grant KTIA\_NAP\_13-1-2013-0001); the Hungarian Academy of Sciences (MTA-SE Neuropsychopharmacology and Neurochemistry Research Group); the Swedish Research Council, Karolinska Institutet; an Unrestricted Bristol-Myers Squibb Neuroscience Grant; a NARSAD Distinguished Investigator Award; the Marianne and Marcus Wallenberg Foundation; and the Knut and Alice Wallenberg Foundation. X.G. is a recipient of the Bolyai Scholarship of the Hungarian Academy of Sciences.

- Kessler RC, et al.; National Comorbidity Survey Replication (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA* 289(23):3095–3105.
- Wittchen HU (2012) The burden of mood disorders. *Science* 338(6103):15.
- Kendler KS (2012) The dappled nature of causes of psychiatric illness: Replacing the organic-functional/hardware-software dichotomy with empirically based pluralism. *Mol Psychiatry* 17(4):377–388.
- Kendler KS (2013) What psychiatric genetics has taught us about the nature of psychiatric illness and what is left to learn. *Mol Psychiatry* 18(10):1058–1066.
- Sullivan PF, Neale MC, Kendler KS (2000) Genetic epidemiology of major depression: Review and meta-analysis. *Am J Psychiatry* 157(10):1552–1562.
- Maes M, Meltzer HY (1995) The serotonin hypothesis of major depression. *Psychopharmacology: The Fourth Generation of Progress*, eds Bloom FE, Kupfer DJ (Raven Press, New York), pp 933–944.
- Schatzberg AF, Schildkraut JJ (1995) Recent studies on norepinephrine systems in mood disorders. *Psychopharmacology: The Fourth Generation of Progress*, eds Bloom FE, Kupfer DJ (Raven Press, New York), pp 911–920.
- Millan MJ (2006) Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. *Pharmacol Ther* 110(2):135–370.
- Trivedi MH, et al.; STAR\*D Study Team (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: Implications for clinical practice. *Am J Psychiatry* 163(1):28–40.
- Burbach JP (2010) Neuropeptides from concept to online database [www.neuropeptides.nl](http://www.neuropeptides.nl). *Eur J Pharmacol* 626(1):27–48.
- Griebel G, Holsboer F (2012) Neuropeptide receptor ligands as drugs for psychiatric diseases: The end of the beginning? *Nat Rev Drug Discov* 11(6):462–478.
- Höckfelt T, Bartfai T, Bloom F (2003) Neuropeptides: Opportunities for drug discovery. *Lancet Neurol* 2(8):463–472.
- Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. *Trends Pharmacol Sci* 24(11):580–588.
- Nemeroff CB, Vale WW (2005) The neurobiology of depression: Inroads to treatment and new drug discovery. *J Clin Psychiatry* 66(Suppl 7):5–13.
- Steckler T (2008) Peptide receptor ligands to treat anxiety disorders. *Handbook of Anxiety and Fear*, eds Blanchard RJ, Blanchard DC, Griebel G, Nutt D (Elsevier, Amsterdam), pp 157–217.
- Griebel G, Holmes A (2013) 50 years of hurdles and hope in anxiolytic drug discovery. *Nat Rev Drug Discov* 12(9):667–687.
- Maubach KA, Rupniak NM, Kramer MS, Hill RG (1999) Novel strategies for pharmacotherapy of depression. *Curr Opin Chem Biol* 3(4):481–488.
- Sajdyk TJ, Shekhar A, Gehlert DR (2004) Interactions between NPY and CRF in the amygdala to regulate emotionality. *Neuropeptides* 38(4):225–234.
- Wu G, et al. (2011) Central functions of neuropeptide Y in mood and anxiety disorders. *Expert Opin Ther Targets* 15(11):1317–1331.
- Ranga K, Krishnan R (2002) Clinical experience with substance P receptor (NK1) antagonists in depression. *J Clin Psychiatry* 63(Suppl 11):25–29.
- Wrenn CC, Crawley JN (2001) Pharmacological evidence supporting a role for galanin in cognition and affect. *Prog Neuropsychopharmacol Biol Psychiatry* 25(1):283–299.
- Tatemoto K, Rökaeus Å, Jörnvall H, McDonald TJ, Mutt V (1983) Galanin—A novel biologically active peptide from porcine intestine. *FEBS Lett* 164(1):124–128.
- Skofitsch G, Jacobowitz DM (1985) Immunohistochemical mapping of galanin-like neurons in the rat central nervous system. *Peptides* 6(3):509–546.
- Melander T, Höckfelt T, Rökaeus A (1986) Distribution of galaninlike immunoreactivity in the rat central nervous system. *J Comp Neurol* 248(4):475–517.
- Kordower JH, Le HK, Mufson EJ (1992) Galanin immunoreactivity in the primate central nervous system. *J Comp Neurol* 319(4):479–500.
- Le Maître E, Barde SS, Palkovits M, Diaz-Heijtz R, Höckfelt TG (2013) Distinct features of neurotransmitter systems in the human brain with focus on the galanin system in locus coeruleus and dorsal raphe. *Proc Natl Acad Sci USA* 110(6):E536–E545.
- Gentleman SM, et al. (1989) Distribution of galanin-like immunoreactivity in the human brain. *Brain Res* 505(2):311–315.
- Melander T, et al. (1986) Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS. *J Neurosci* 6(12):3640–3654.
- Lundberg JM (1996) Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. *Pharmacol Rev* 48(1):113–178.
- Khoshbouei H, Cecchi M, Morilak DA (2002) Modulatory effects of galanin in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. *Neuropsychopharmacology* 27(1):25–34.
- Holmes PV, Blanchard DC, Blanchard RJ, Brady LS, Crawley JN (1995) Chronic social stress increases levels of preprogalanin mRNA in the rat locus coeruleus. *Pharmacol Biochem Behav* 50(4):655–660.
- Sweerts BW, Jarrott B, Lawrence AJ (1999) Expression of preprogalanin mRNA following acute and chronic restraint stress in brains of normotensive and hypertensive rats. *Brain Res Mol Brain Res* 69(1):113–123.
- Lang R, Gundlach AL, Kofler B (2007) The galanin peptide family: Receptor pharmacology, pleiotropic biological actions, and implications in health and disease. *Pharmacol Ther* 115(2):177–207.
- Brancheck TA, Smith KE, Gerald C, Walker MW (2000) Galanin receptor subtypes. *Trends Pharmacol Sci* 21(3):109–117.
- O'Donnell D, et al. (2003) Localization of galanin receptor subtypes in the rat CNS. *Handbook of Chemical Neuroanatomy, Vol. 20, Peptide Receptors, Part II*, eds Quirion R, Björklund A, Höckfelt T (Elsevier, Amsterdam), pp 195–244.
- Köhler C, et al. (1989) Distribution of galanin-binding sites in the monkey and human telencephalon: Preliminary observations. *Exp Brain Res* 75(2):375–380.
- Fuxe K, et al. (1998) Galanin modulates 5-hydroxytryptamine functions. Focus on galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the brain. *Ann N Y Acad Sci* 863:274–290.
- Kuteeva E, Höckfelt T, Wardi T, Ögren SO (2010) Galanin, galanin receptor subtypes and depression-like behaviour. *EXS* 102:163–181.
- Lu X, Sharkey L, Bartfai T (2007) The brain galanin receptors: Targets for novel antidepressant drugs. *CNS Neurol Disord Drug Targets* 6(3):183–192.
- Weiss JM, Bonsall RW, Demetrikopoulos MK, Emery MS, West CH (1998) Galanin: A significant role in depression? *Ann N Y Acad Sci* 863:364–382.
- Kozlovsky N, Matar MA, Kaplan Z, Zohar J, Cohen H (2009) The role of the galanergic system in modulating stress-related responses in an animal model of posttraumatic stress disorder. *Biol Psychiatry* 65(5):383–391.
- Murck H, et al. (2004) Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. *Psychoneuroendocrinology* 29(9):1205–1211.
- Belfer I, et al. (2007) Alcoholism is associated with GALR3 but not two other galanin receptor genes. *Genes Brain Behav* 6(5):473–481.
- Belfer I, et al. (2006) Association of galanin haplotypes with alcoholism and anxiety in two ethnically distinct populations. *Mol Psychiatry* 11(3):301–311.
- Levrain O, et al. (2008) Genetic susceptibility to heroin addiction: A candidate gene association study. *Genes Brain Behav* 7(7):720–729.
- Jackson KJ, Chen X, Miles MF, Harenza J, Damaj MI (2011) The neuropeptide galanin and variants in the GalR1 gene are associated with nicotine dependence. *Neuropsychopharmacology* 36(11):2339–2348.

47. Lori A, et al. (2011) The galanin receptor 1 gene associates with tobacco craving in smokers seeking cessation treatment. *Neuropsychopharmacology* 36(7):1412–1420.
48. Unschuld PG, et al. (2008) Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder. *J Affect Disord* 105(1–3):177–184.
49. Unschuld PG, et al. (2010) Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. *Neuropsychopharmacology* 35(7):1583–1592.
50. Max MB, et al. (2006) A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. *Mol Pain* 2:14.
51. Davidson S, et al. (2011) Differential activity by polymorphic variants of a remote enhancer that supports galanin expression in the hypothalamus and amygdala: Implications for obesity, depression and alcoholism. *Neuropsychopharmacology* 36(11):2211–2221.
52. Quinn JP, Warburton A, Myers P, Savage AL, Bubbs VJ (2013) Polymorphic variation as a driver of differential neuropeptide gene expression. *Neuropeptides* 47(6):395–400.
53. McCarroll SA, Hyman SE (2013) Progress in the genetics of polygenic brain disorders: Significant new challenges for neurobiology. *Neuron* 80(3):578–587.
54. Ripke S, et al.; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium (2013) A mega-analysis of genome-wide association studies for major depressive disorder. *Mol Psychiatry* 18(4):497–511.
55. Wray NR, et al. (2012) Genome-wide association study of major depressive disorder: New results, meta-analysis, and lessons learned. *Mol Psychiatry* 17(1):36–48.
56. Plomin R, Haworth CM, Davis OS (2009) Common disorders are quantitative traits. *Nat Rev Genet* 10(12):872–878.
57. Belsky J, et al. (2009) Vulnerability genes or plasticity genes? *Mol Psychiatry* 14(8):746–754.
58. Verzilli CJ, Stallard N, Whittaker JC (2006) Bayesian graphical models for genome-wide association studies. *Am J Hum Genet* 79(1):100–112.
59. Viallefond V, Raftery AE, Richardson S (2001) Variable selection and Bayesian model averaging in case-control studies. *Stat Med* 20(21):3215–3230.
60. Acid S, De Campos LM, Castellano JG (2005) Learning Bayesian network classifiers: Searching in a space of partially directed acyclic graphs. *Mach Learn* 59(3):213–253.
61. Ungvári I, et al. (2012) Evaluation of a partial genome screening of two asthma susceptibility regions using bayesian network based Bayesian multilevel analysis of relevance. *PLoS ONE* 7(3):e33573.
62. Lesch KP, et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. *Science* 274(5292):1527–1531.
63. Karg K, Burmeister M, Shedden K, Sen S (2011) The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. *Arch Gen Psychiatry* 68(5):444–454.
64. Lazary J, et al. (2008) New evidence for the association of the serotonin transporter gene (SLC6A4) haplotypes, threatening life events, and depressive phenotype. *Biol Psychiatry* 64(6):498–504.
65. Caspi A, et al. (2003) Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. *Science* 301(5631):386–389.
66. Hamon M, Blier P (2013) Monoamine neurocircuitry in depression and strategies for new treatments. *Prog Neuropsychopharmacol Biol Psychiatry* 45:54–63.
67. Borroto-Escuela DO, et al. (2010) Galanin receptor-1 modulates 5-hydroxytryptamine-1A signaling via heterodimerization. *Biochem Biophys Res Commun* 393(4):767–772.
68. Pieribone VA, et al. (1995) Galanin induces a hyperpolarization of norepinephrine-containing locus coeruleus neurons in the brainstem slice. *Neuroscience* 64(4):861–874.
69. Vila-Porcile E, et al. (2009) Dendritic synthesis and release of the neuropeptide galanin: Morphological evidence from studies on rat locus coeruleus neurons. *J Comp Neurol* 516(3):199–212.
70. Coumis U, Davies CH (2002) The effects of galanin on long-term synaptic plasticity in the CA1 area of rodent hippocampus. *Neuroscience* 112(1):173–182.
71. Swanson CJ, et al. (2005) Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. *Proc Natl Acad Sci USA* 102(48):17489–17494.
72. Xu ZQ, Zhang X, Pieribone VA, Grillner S, Hökfelt T (1998) Galanin-5-hydroxytryptamine interactions: Electrophysiological, immunohistochemical and in situ hybridization studies on rat dorsal raphe neurons with a note on galanin R1 and R2 receptors. *Neuroscience* 87(1):79–94.
73. Frodl T, et al. (2002) Hippocampal changes in patients with a first episode of major depression. *Am J Psychiatry* 159(7):1112–1118.
74. Hajszan T, et al. (2009) Remodeling of hippocampal spine synapses in the rat learned helplessness model of depression. *Biol Psychiatry* 65(5):392–400.
75. Sheline YI, Sanghavi M, Mintun MA, Gado MH (1999) Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. *J Neurosci* 19(12):5034–5043.
76. Arnone D, et al. (2013) State-dependent changes in hippocampal grey matter in depression. *Mol Psychiatry* 18(12):1265–1272.
77. Castrén E (2004) Neurotrophic effects of antidepressant drugs. *Curr Opin Pharmacol* 4(1):58–64.
78. Hajszan T, MacLusky NJ (2006) Neurologic links between epilepsy and depression in women: Is hippocampal neuroplasticity the key? *Neurology* 66(6, Suppl 3):S13–S22.
79. Nestler EJ, et al. (2002) Neurobiology of depression. *Neuron* 34(1):13–25.
80. Elliott-Hunt CR, et al. (2004) Galanin acts as a neuroprotective factor to the hippocampus. *Proc Natl Acad Sci USA* 101(14):5105–5110.
81. Mazarati AM, et al. (1998) Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. *J Neurosci* 18(23):10070–10077.
82. Pironi S, et al. (2005) The galanin-R2 agonist AR-M1896 reduces glutamate toxicity in primary neural hippocampal cells. *J Neurochem* 95(3):821–833.
83. Elliott-Hunt CR, Pope RJ, Vanderplank P, Wynick D (2007) Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. *J Neurochem* 100(3):780–789.
84. Gage FH (2000) Mammalian neural stem cells. *Science* 287(5457):1433–1438.
85. Ming GL, Song H (2005) Adult neurogenesis in the mammalian central nervous system. *Annu Rev Neurosci* 28:223–250.
86. Duman RS, Malberg J, Thome J (1999) Neural plasticity to stress and antidepressant treatment. *Biol Psychiatry* 46(9):1181–1191.
87. Jacobs BL, van Praag H, Gage FH (2000) Adult brain neurogenesis and psychiatry: A novel theory of depression. *Mol Psychiatry* 5(3):262–269.
88. Malberg JE, Schechter LE (2005) Increasing hippocampal neurogenesis: A novel mechanism for antidepressant drugs. *Curr Pharm Des* 11(2):145–155.
89. Abbosh C, Lawkowski A, Zaben M, Gray W (2011) GalR2/3 mediates proliferative and trophic effects of galanin on postnatal hippocampal precursors. *J Neurochem* 117(3):425–436.
90. Hobson SA, et al. (2008) Galanin acts as a trophic factor to the central and peripheral nervous systems. *Cell Mol Life Sci* 65(12):1806–1812.
91. Mansouri S, et al. (2013) GalR3 activation promotes adult neural stem cell survival in response to a diabetic milieu. *J Neurochem* 127(2):209–220.
92. Spalding KL, et al. (2013) Dynamics of hippocampal neurogenesis in adult humans. *Cell* 153(6):1219–1227.
93. Eriksson PS, et al. (1998) Neurogenesis in the adult human hippocampus. *Nat Med* 4(11):1313–1317.
94. Anisimov SV, et al. (2002) SAGE identification of gene transcripts with profiles unique to pluripotent mouse R1 embryonic stem cells. *Genomics* 79(2):169–176.
95. Assou S, et al. (2007) A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. *Stem Cells* 25(4):961–973.
96. Lundström L, Elmquist A, Bartfai T, Langel U (2005) Galanin and its receptors in neurological disorders. *Neuromolecular Med* 7(1–2):157–180.
97. Badie-Mahdavi H, Lu X, Behrens MM, Bartfai T (2005) Role of galanin receptor 1 and galanin receptor 2 activation in synaptic plasticity associated with 3',5'-cyclic AMP response element-binding protein phosphorylation in the dentate gyrus: Studies with a galanin receptor 2 agonist and galanin receptor 1 knockout mice. *Neuroscience* 133(2):591–604.
98. Kinney JW, et al. (2009) Impairment of memory consolidation by galanin correlates with in vivo inhibition of both LTP and CREB phosphorylation. *Neurobiol Learn Mem* 92(3):429–438.
99. Hawes JJ, et al. (2008) Galanin protects against behavioral and neurochemical correlates of opiate reward. *Neuropsychopharmacology* 33(8):1864–1873.
100. Castrén E, Rantamäki T (2010) Role of brain-derived neurotrophic factor in the aetiology of depression: Implications for pharmacological treatment. *CNS Drugs* 24(1):1–7.
101. Martinowich K, Manji H, Lu B (2007) New insights into BDNF function in depression and anxiety. *Nat Neurosci* 10(9):1089–1093.
102. Juhasz G, et al. (2011) The CREB1-BDNF-NTRK2 pathway in depression: Multiple gene-cognition-environment interactions. *Biol Psychiatry* 69(8):762–771.
103. Juhasz G, et al. (2009) CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. *Neuropsychopharmacology* 34(8):2019–2027.
104. Heim C, Nemeroff CB (2001) The role of childhood trauma in the neurobiology of mood and anxiety disorders: Preclinical and clinical studies. *Biol Psychiatry* 49(12):1023–1039.
105. Brugha T, Bebbington P, Tennant C, Hurry J (1985) The list of threatening experiences: A subset of 12 life event categories with considerable long-term contextual threat. *Psychol Med* 15(1):189–194.
106. Derogatis LR (1993) *BSI: Brief Symptom Inventory: Administration, Scoring, and Procedures Manual* (National Computer Systems Pearson, Minneapolis, MN).
107. Bernstein DP, et al. (1994) Initial reliability and validity of a new retrospective measure of child abuse and neglect. *Am J Psychiatry* 151(8):1132–1136.
108. Freeman B, et al. (2003) DNA from buccal swabs recruited by mail: Evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. *Behav Genet* 33(1):67–72.